Non-clear cell renal cell carcinoma (RCC) accounts for about 25% of all RCC diagnoses and usually has worse outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have shown preliminary activity in non-clear cell RCC. Cabozantinib appears to enhance the response to immune checkpoint inhibitors and has shown encouraging results in combination with […]
Nivolumab alone and in combination with ipilimumab is used for the treatment of patients with metastatic renal cell carcinoma (RCC). However, most patients with non-clear cell RCC are excluded from clinical trials, and there is limited data on the effectiveness of nivolumab for the treatment of these patients. This phase IIIb/IV CheckMate 374 study was conducted to look at […]
This article nicely summarises the most exciting research highlights from the ASCO 2020 Virtual Scientific Programme which demonstrate the evolution of treatments for advanced renal cell carcinoma (RCC), with a focus on combination treatments, salvage therapies and treatments for non-clear cell RCC. Read the review article in the Journal of Clinical Oncology here
In this video interview, Dr Monty Pal from the City of Hope cancer centre in California, USA, talks about the clinical trials involving cabozantinib in combination with atezolizumab for clear cell and non-clear cell renal cell carcinoma (RCC). Watch the video interview on Practice Update here
There are more than 10 different subtypes of renal cell carcinoma (RCC), each with important genetic differences that determine how aggressive they are or their response to treatment. Clear cell RCC is the most common subtype, accounting for 75-80% of cases. A team of scientists at the University of Michigan, USA, have discovered the gene […]
In this video interview from Practice Update, Dr Brad McGregor from Dana-Faber Cancer Institute in Boston, USA, talks about the results from a phase 2 trial with the combination of atezolizumab plus bevacizumab in patients with metastatic non-clear cell renal cell carcinoma (RCC). The study enrolled 60 patients, 42 of which had non-clear cell RCC […]
Nivolumab alone and in combination with ipilimumab is used for the treatment of patients with metastatic renal cell carcinoma (RCC) in the second- and first-line, respectively. However, since patients with non-clear cell RCC are excluded from clinical trials, there is limited data on the effectiveness of nivolumab for the treatment of these patients. In a […]
The majority of renal cell carcinomas (RCCs) are a subtype called clear cell RCC. Most drugs have been developed to treat this subtype of RCC, leaving people with other metastatic RCC subtypes with an unmet need for an effective treatment in the first-line. Papillary RCC (pRCC) represents 10-15% of renal cell carcinomas, and is not an insignificant subtype. […]
Overall survival results from a study with a combination of savolitinib and durvalumab for papillary renal cell carcinoma (RCC) patients were reported at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held in San Francisco last weekend. Metastatic papillary RCC has poor outcomes and there is need for new treatments. In this phase 1/2 study (CALYPSO), a […]
Papillary renal cell carcinoma (PRCC) is a rare subtype of renal cell carcinoma (RCC), accounting for 10%-15% of all cases of RCC. There are two types of papillary RCC; type 1 and type 2. Currently, there is an unmet need for an effective first-line treatment for metastatic PRCC. A recent phase 2 study, published in […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
